Blog

Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions. With the highest rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug and play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent and real-world data capture.

Proximie

Proximie is a technology platform that uses a combination of machine learning, artificial intelligence and augmented reality to allow clinicians to virtually ‘scrub in’ and collaborate with each other from anywhere in the world.

Leyden Labs

Leyden Labs platform targets commonalities of viral families to protect humanity from known and future viruses.

Odaseva

Odaseva partners with the largest and most sophisticated organizations in the world to accelerate their trust in business-critical cloud applications. Fortune Global 500 industry leaders use Odaseva technology to back up and restore data, ensure data privacy and regulatory compliance, and use data to drive operational agility. Engineered for Salesforce by Salesforce experts and endorsed by Salesforce Ventures, Odaseva is trusted by 30+ million users and has received 100% five-star reviews over eight years on the Salesforce AppExchange.

Funnel

Funnel’s product is a Data Core used by 800 forward-thinking organizations across a wide set of industry verticals to automatically import marketing data and make it Business-Ready. The Swedish Software-as-a-Service (SaaS) company was founded by Fredrik Skantze and Per Made in 2014. Funnel has 140 employees and offices in Stockholm and Boston.

Arvelle Therapeutics

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market.  Arvelle Therapeutics was acquired by Angelini Pharma in January 2021.

Owkin

Owkin combines life-science and machine learning expertise to make drug development and clinical trial design more targeted and more cost effective. Owkin’s machine learning algorithms create models that predict disease evolution and treatment outcomes. These predictive models are implemented in clinical trials for enhanced analysis, surrogate endpoints, patient stratification, patient selection, and high-value subgroup identification. The impact of this research is faster discovery of better treatments at a lower cost.

Genomics Ltd

Genomics plc’s vision is to use genomic insights to transform the drug discovery industry by getting better drugs developed more quickly and targeted at the right group of patients.

Rezera

Rezera, formely Nodthera, is a clinical-stage biotechnology company developing a portfolio of internally-invented and wholly-owned oral inhibitors of NLRP3 to address inflammatory drivers of cardiovascular and neurologic diseases driven by the NLRP3 inflammation pathway. The Company’s lead program, ruvonoflast (f/k/a NT-0796), completed its Phase 2 RESOLVE-1 and RESOLVE-2 trials. The Company is also advancing trabzanoflast (f/k/a NT-0150) for treatment of neurologic diseases.

Rezera is headquartered in Boston, Massachusetts, with an R&D base in Cambridge, UK.

Lighthouse

Lighthouse (formerly OTA Insight) is the leading commercial platform for the travel & hospitality industry. We transform complexity into confidence by providing actionable market insights, business intelligence, and pricing tools that maximize revenue growth. We continually innovate to deliver the best platform for hospitality professionals to price more effectively, measure performance more efficiently, and understand the market in new ways. Trusted by over 65,000 hotels in 185 countries, Lighthouse is the only solution that provides real-time hotel and short-term rental data in a single platform. We strive to deliver the best possible experience with unmatched customer service. We consider our clients as true partners—their success is our success.